Midatech Pharma PLC Announces Notice of Interim Results

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ABINGDON, OXFORDSHIRE / ACCESSWIRE / August 28, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will announce its interim results for the six months ended 30 June 2020 on 10 September 2020.

The Company will host an investor conference call at 2.00pm on the day of the results, details of which will be announced in due course.

For more information, please contact:

Midatech Pharma PLC

Stephen Stamp, CEO, CFO

Tel: +44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

 

Turner Pope Investments (TPI) Limited (Joint Broker)

Andrew Thacker (Corporate Broking)

Tel: +44(0)20 3657 0050

 

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

 

Edison Group (US Investor Relations)

Megan Paul

Tel: (646) 653 7034

Email: mpaul@edisongroup.com

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM:MTPH; and NASDAQ:MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company’s technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

· Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

· MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

· MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.

The platform nature of the technologies allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech’s technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech’s headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Midatech Pharma PLC

View source version on accesswire.com:
https://www.accesswire.com/603758/Midatech-Pharma-PLC-Announces-Notice-of-Interim-Results

Staff

Recent Posts

Prime Biome Warns Consumers About Unauthorized Sellers and Ensures Commitment to Product Authenticity

NEW YORK, March 15, 2025 /PRNewswire/ -- The official brand behind Prime Biome, a product developed…

3 hours ago

SmartSKN Launches K-OWN: The World’s first AI custom Korean skincare platform powered by robots

BOSTON, March 14, 2025 /PRNewswire/ -- SmartSKN, a leader in K-Beauty technology, announces the launch…

15 hours ago

Nimblemind.ai Raises $2.5M to Unlock AI-Ready Clinical Data for Healthcare Providers

CHICAGO, March 14, 2025 /PRNewswire/ -- Nimblemind.ai, an AI-powered data infrastructure platform designed to help…

15 hours ago

AI-Powered Healthcare: How ADLINK’s Medical Innovations at HIMSS 2025 Are Transforming Patient Care

Celebrating 30 Years of Innovation Excellence with Advanced OEM Solutions for Healthcare Summary: Successful Showcase:…

15 hours ago

CTG Appoints Dan Stoke Vice President of U.S. Healthcare Business

Growth-Oriented Healthcare IT Leader to Build on CTG’s Strong Industry Legacy; Drive Growth, Innovation, and…

18 hours ago

TruBridge Announces Participation in the KeyBanc Capital Markets Healthcare Forum

MOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ:TBRG), a healthcare solutions company, today announced that management will participate…

18 hours ago